A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

NCT04166006 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Head Neck Tumors
Neuroendocrine Tumors
Soft Tissue Sarcoma
Rare Cancer
Vaccination

Interventions

BIOLOGICAL: Autologous DC vaccine
DRUG: Interleukin-2

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS